ReachMD

Dr. Jennifer Green is a professor of medicine in the Division of Endocrinology at Duke University and a faculty member of the Duke Clinical Research Institute. Her research has focused on strategies to treat diabetes and reduce the risks of cardiovascular, kidney, and other diabetes-related complications. Her work with the DCRI has included protocol development, oversight of adjudication committees, and clinical and operational leadership for several large, international trials designed to determine the cardiovascular effects of glucose-lowering medications (TECOS, EXSCEL, and Harmony Outcomes). She currently serves as the U.S. coordinating center PI and U.S. national representative for the EMPA-Kidney trial of empagliflozin therapy in patients with chronic kidney disease. EMPA-Kidney found that empagliflozin reduced the risk of a composite cardiorenal outcome in a broad spectrum of individuals with chronic kidney disease, with or without diabetes; a long-term follow-up study of the participants is ongoing.

Dr. Green is also part of the multidisciplinary leadership team for COORDINATE-Diabetes, a trial which was successful in increasing delivery of several guideline-based therapies (including high intensity statin, ACEi/ARB, and SGLT2i or GLP-1RA) to patients with T2D and ASCVD who received care in cardiology clinics across the U.S. She’s now leading an innovative, centralized, siteless study of an intervention to reduce the risk of future diabetic foot ulceration, which will be conducted using an EHR-linked software platform to assess clinical outcomes. Dr. Green has concluded three years of service as a member of the American Diabetes Association’s (ADA) Professional Practice Committee, which publishes the organization’s annual Standards of Care in Diabetes. She’s now a member of the international ADA-EASD writing group, which recently revised a joint consensus statement on the management of hyperglycemia in type 2 diabetes.